CarepathRx has joined Evernorth Health Services, a division of the Cigna Group. According to a statement to Becker’s from Evernorth, the acquisition was completed in 2025 as part of the company’s strategy to expand support for patients with specialty conditions…
Pharmacy
The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept.…
Over the next three to five years, the chief pharmacy officer role is expected to expand well beyond operational oversight. Dispensing excellence and medication safety will remain foundational. But what will distinguish successful leaders in 2026 and beyond is enterprise-level…
The Department of Justice filed a brief supporting AbbVie in its appeal challenging Colorado’s 340B Contract Pharmacy Protection Act. In a Feb. 25 filing with the 10th U.S. Circuit Court of Appeals, the department argued the Colorado law is preempted…
Ascension, based in St. Louis, expanded the Dispensary of Hope program across its Ascension Rx pharmacy network, bringing the total number of participating Ascension Rx pharmacies to 35 across nine states. Over the past six months, 11 Ascension Rx pharmacy…
Advertisement
CVS Caremark is expanding its use of Surescripts’ Touchless Prior Authorization platform to accelerate approvals for select specialty medications. The prior authorization technology connects directly to patients’ EHRs to gather required clinical data and match it with prior authorization criteria,…
The U.S. District Court for the District of Hawaii denied AstraZeneca’s request to block a state law protecting 340B contract pharmacy arrangements. In its ruling, issued Feb. 23, the court found that Hawaii’s Act 29 is not preempted by federal…
The Health Resources and Services Administration has extended the comment period on its 340B rebate model proposal from 30 days to 60 days after the American Hospital Association and other organizations requested more time. The deadline for comments is now…
The Supreme Court’s Feb. 20 ruling against President Donald Trump’s use of emergency powers to impose tariffs marked a major legal setback, but it is not a full reprieve for hospital leaders and pharmaceutical manufacturers navigating global supply chains. In…
The FDA has placed a partial clinical hold on a cancer drug trial following four safety events, including one death, according to a Feb. 25 announcement from MacroGenics. The partial hold pauses enrollment for MacroGenics’ phase 2 study on lorigerlimab,…